TABLE 3.

HVAD vs. HM3: Non-adjust and adjusted Cox-regression analysis for major adverse events at follow-up.

Adverse event	Non-Adjusted Cox-regression		Adjusted a Cox-regression
	HVAD vs. HM3 HR (95% CI)	p	HVAD vs. HM3 HR (95% CI)	p
Mortality	1.6 [1.16–2.17]	0.004	1.5 [1.2–1.9]	0.031
Haemorrhagic stroke	3.04 [1.6–5.8]	<0.001	2.6 [1.3–4.9]	0.005
Ischaemic stroke	1.8 [0.97–3.5]	0.058	2.08 [1.06–4.08]	0.033
Pump Thrombosis	27.7 [3.8–203.8]	0.001	25.7 [3.4–188.9]	<0.001
GI bleeding	2.4 [1.2–4.5]	0.01	1.6 [0.81–3.2]	0.17
RV failure	1.14 [0.77–1.7]	0.51	0.96 [0.62–1.4]	0.83
DL infection	1.3 [0.88–1.89]	0.2	1.3 [0.85–2.04]	0.21

^a Adjusted for age, BSA, ALT, creatinine, primary heart disease, sPAP.

DL, driveline; GI, gastrointestinal; RV, right ventricle.

*Statistically significant.